Practice Updates in Ovarian Cancer

Experts in gynecologic oncology review clinical cases in ovarian carcinoma, focusing on individualized approaches to the use of PARP inhibition in the first-line maintenance setting and key clinical trials.

EP. 1: Case 1: Stage IV, High-Grade, Serous Epithelial Ovarian Cancer

January 28th 2022

Dr Thomas C. Krivak reviews a case of a 59-year-old woman who has stage IV, high-grade serous epithelial ovarian cancer and discusses ASCO and NCCN guideline recommendations for germline/somatic tumor testing.

EP. 2: Case 1: Testing for BRCA Mutations and HRD in Advanced Ovarian Cancer

January 28th 2022

Cecelia H. Boardman, MD, John K. Chan, MD, and Ashley Farione, PA-C, discuss their treatment approach to genetic testing in patients with advanced ovarian cancer.

EP. 3: Case 1: First-Line Maintenance Therapy in Advanced Ovarian Cancer

January 28th 2022

John K. Chan, MD, leads a discussion on the role of first-line maintenance therapy for advanced ovarian cancer and the standard of care first-line maintenance approaches for a patient with gBRCA2-mutated disease.

EP. 4: Case 1: Factors for Selecting First-Line Maintenance Therapy in Advanced Ovarian Cancer

January 28th 2022

A panel of experts share insight on patient factors to consider when selecting first-line maintenance therapy for advanced ovarian cancer.

EP. 5: Case 1: Key Clinical Trials for PARP Inhibitors in Advanced Ovarian Cancer

January 28th 2022

Experts in gynecologic oncology review data and clinical implications for the use of PARP inhibitors from the GOG-0218, SOLO-1, PRIMA, and PAOLA-1 trials in advanced ovarian cancer.

EP. 6: Case 1: Guideline Recommendations for PARP Inhibitor Use in Ovarian Cancer

January 28th 2022

Thomas C. Krivak, MD, leads a discussion on guideline recommendations regarding the use of PARP inhibitors in newly diagnosed advanced ovarian cancer.

EP. 7: Case 1: Using Niraparib Maintenance Therapy in Ovarian Cancer

January 28th 2022

Cecelia H. Boardman, MD, John K. Chan, MD, and Thomas C. Krivak, MD, provide insight on dosing schedules for niraparib maintenance in advanced ovarian cancer.

EP. 8: Case 2: Stage III, High-Grade Serous Epithelial Ovarian Cancer

February 4th 2022

Experts in gynecologic oncology review the case of a 71-year-old woman who is diagnosed with stage III, high-grade serous epithelial ovarian cancer, and comment on their approach to genetic testing in the frontline setting.

EP. 9: Case 2: Maintenance Strategies for Advanced Ovarian Cancer

February 4th 2022

Thomas C. Krivak, MD; John K. Chan, MD; Cecelia H. Boardman, MD; and Ashley Farione, PA-C, review the optimal approach to maintenance therapeutic options for a patient with stage III, high-grade serous epithelial ovarian cancer.

EP. 10: Case 2: Monitoring Adverse Reactions With Niraparib Maintenance in Ovarian Cancer

February 4th 2022

Cecelia H. Boardman, MD, John K. Chan, MD, and Thomas C. Krivak, MD, share strategies for monitoring adverse events and the optimal duration for niraparib maintenance therapy for a patient with advanced ovarian cancer.